• 1
    Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 2009; 28: 35567
  • 2
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 22549
  • 3
    von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 306877
  • 4
    McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 18537
  • 5
    Youssef RF, Mitra AP, Bartsch G Jr et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27: 920
  • 6
    Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008; 113: 128493
  • 7
    Philips S, Sanford B, Halabi S et al. Phase II study of cisplatin, gemcitabine and gefitinib for advanced urothelial carcinoma: Analysis of the second cohort of CALGB 90102. J Clin Oncol (Meeting Abstracts) 2006 24 (18S): 4578
  • 8
    Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 221824
  • 9
    Bradley DA, Dunn R, Nanus D et al. Randomized, double-blind, placebocontrolled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer 2007; 5: 4603
  • 10
    Gallagher DJ, Milowsky MI, Gerst SR et al. Final results of a phase II study of sunitinib in patients with relapsed or refractory urothelial carcinoma. J Clin Oncol (Meeting Abstracts) 2008 26 (15S): 5082
  • 11
    Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009; 27: 3919
  • 12
    Chiong E, Lee I-L, Dadbin A et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. J Urol 2009; 181: (4 Suppl.): 406 (abstract)
  • 13
    Patel AR, Larchian WA, Smith AK et al. Quantification of Sunitinib’s antitumor effects in a localized orthotopic bladder cancer model. J Urol 2009; 181: (4 Suppl):409 (abstract)
  • 14
    Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8: 233947
  • 15
    Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 306: re12
  • 16
    Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7: 134754
  • 17
    Bochner BH, Cote RJ, Weidner N et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87: 160312
  • 18
    Nguyen M, Watanabe H, Budson AE et al. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993; 85: 2412
  • 19
    Motzer RJ, Molina AM. Targeting renal cell carcinoma. J Clin Oncol 2009; 27: 32746
  • 20
    Mabuchi S, Altomare DA, Cheung M et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 426170
  • 21
    Fechner G, Classen K, Schmidt D et al. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009; 73: 6658
  • 22
    Cloughesy TF, Yoshimoto K, Nghiemphu P et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Med 2008; 5: e8
  • 23
    Wu X, Obata T, Khan Q, Highshaw RA et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004; 93: 14350
  • 24
    Chai CY, Chen WT, Hung WC et al. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 2008; 61: 65864
  • 25
    Ioachim E, Michael M, Salmas M et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol Int 2006; 77: 25563
  • 26
    Nadaoka J, Horikawa Y, Saito M et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 2008; 122: 1297302
  • 27
    Tickoo SK, Alden D, Olgac S et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol 2007; 177: 125863
  • 28
    Ma L, Teruya-Feldstein J, Bonner P et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase–mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007; 67: 710612
  • 29
    Bellmunt J, Maroto P, Mellado B et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO, Genitourinary Cancers Symposium, 2008 (abstract)
  • 30
    Hahn NM, Stadler WM, Zon RT et al. A multicentric phase II study of cisplatin, gemcitabine and bevacizumab as first-line chemotherapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU-0475. J Clin Oncol 2009; 27: 15 s (suppl; abstr 5018)
  • 31
    Jones RJ, Tamsin B, Fennell M et al. The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol 2008; 61: 2332
  • 32
    Pinter F, Papay J, Almasi A et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008; 10: 1608